Medtech


June 16, 2026

EW: TAVR Draft Coverage Puts & Takes

By John Leppard

CMS’s draft coverage policy for transcatheter aortic valve replacement (TAVR) appears largely consistent with our initial expectations, likely bringing some incremental upside as well. If finalized largely as proposed in Sept., as seems probable, we…

Read More >>

June 11, 2026

[EW, MDT, ABT] TAVR: Incremental Gains From Expected Coverage

By John Leppard

In advance of the CMS draft coverage decision for transcatheter aortic valve replacement (TAVR) due June 15 (final Sept. 15), we expect policy changes that – while positive – may be more incremental in their…

Read More >>

June 10, 2026

GKOS iDose: MAC Pushback Persists

By John Leppard

We see little reason to alter our base case regarding Medicare coverage of GKOS’s iDose following yesterday’s first contractor open meeting on the five-MAC draft LCD issued in late May. While we believe the MACs…

Read More >>

June 3, 2026

DXCM: What to Expect When You’re Expecting CGM Coverage

By John Leppard

In advance of Dexcom’s (DXCM) readout of its CONNECT RCT this weekend, which management positions as a “powerful anchor” for broader Medicare CGM coverage in “all people with diabetes,” we ultimately expect a material increase…

Read More >>

May 28, 2026

INSP: Noridian’s Modifier & Service Date Inconsistencies

By John Leppard

With Noridian (17% of services) including instructions that physicians bill for Inspire Medical’s (INSP) Inspire V procedure with a -52 (reduced work / payment) modifier this morning, following a similar update from WPS on May…

Read More >>

May 26, 2026

GKOS: iDose LCD & Laser Headwinds

By John Leppard

Following last week’s draft LCDs requiring Glaukos (GKOS) iDose patients to first fail ≥ 2 topical medications and selective laser trabeculoplasty (SLT), the absence of reliable data on the proportion of existing patients that can…

Read More >>

May 21, 2026

GKOS: iDose Coverage & Second Line Therapy

By John Leppard

The draft local coverage decision (LCD) issued today by five MACs with jurisdiction over ~70% of Glaukos (GKOS) Medicare FFS volumes is both better and worse than we had anticipated for the company’s growing iDose…

Read More >>

May 15, 2026

INSP: New Code Denial & Implications

By John Leppard

With today’s rejection of INSP’s coding application for the Inspire V device by the AMA, the company’s last opportunity to have a new code take effect by Jan. 1, 2028 will be to secure approval…

Read More >>

May 7, 2026

iRhythm (IRTC): Final LCD Signals Relief, Modest Headwind

By John Leppard

We suspect iRhythm (IRTC) faces both relief and little more than a modest growth headwind following a finalized local coverage determination (LCD) from its primary Medicare Administrative Contractor (MAC) this morning. In keeping with expectations…

Read More >>

May 7, 2026

INSP: MAC Modifier Mandate

By John Leppard

Medicare Administrative Contractor (WPS) WPS – with jurisdiction over ~13% of INSP implants – this morning updated its hypoglossal nerve LCD billing article to instruct physicians to bill for Inspire V services with a -52…

Read More >>